Considering your sample size prior to moving into the preclinical phase will reap big benefits further down your development program timeline.
Have you ever wondered about a collaborative approach to drug discovery? Integrated drug discovery (IDD) programs could be your answer.
Dr. Brian Roche, PhD, DSP, DABT, has more than 18 years of experience in cardiovascular, respiratory and CNS safety pharmacology research.
Charles River possesses strong analytical capabilities to thoroughly assess the physicochemical properties of complex proteins, which allows for the development of robust product formulations.
We are committed to providing testing and regulatory support to companies developing biosimilar products. Recently published articles highlight our insights and key considerations for biosimilar companies.
When pressure comes to increase efficiency, you may turn to insourcing, outsourcing or a mix of both. Keeping visibility of your testing programs, however, is still important. RightSource℠ helps you find balance between these options to reduce costs, retain visibility and focus on your core competencies.
Dr. Scott Fountain joined our team as executive director of North American laboratory sciences and clinical support for safety assessment. He will ensure the quality and alignment of laboratory sciences across Charles River.
Charles River entered a collaboration with Quintiles and City of Hope, with funding from the California Institute for Regenerative Medicine (CIRM), to establish the Translating Center in San Diego, CA, which offers end-to-end nonclinical, clinical and manufacturing services for stem-cell-based projects.
In several poster presentations, Charles River demonstrated how new immune checkpoint inhibitor data enhances our humanized oncology models, and provided a detailed overview of our current PDX models.
This video presentation of our poster, presented at Neuroscience 2016, outlines how touchscreen testing and MR spectroscopy were used to detect reduced cognition and altered brain metabolites in the CVN mouse model of Alzheimer's disease.